Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19

Table 2 Comparison of laboratory examination results of coronavirus disease 2019 patients currently using different antihypertensive drugs

	Group A, n = 19	Group B, n = 28	t- or U-value	P value
White blood cells	6.64 ± 3.65	6.55 ± 1.82	0.095	0.925
Neutrophils	4.47 ± 3.24	4.20 ± 1.61	0.329	0.744
Lymphocytes	1.54 ± 0.64	1.65 ± 0.40	−0.649	0.522
Neutrophil percentage	64.16 ± 10.59	62.15 ± 8.09	0.677	0.503
Lymphocyte percentage	25.64 ± 9.08	26.06 ± 6.30	−0.168	0.868
C-reactive protein	1.67 (0.97, 9.11)	2.00 (1.00, 2.00)	187	0.316
Markers of myocardial infarction	-	-	-	-
Myoglobin	13.13 ± 15.40	9.16 ± 5.96	0.657	0.532
Hypersensitive troponin	0.16 ± 0.37	0.01 ± 0.001	1.107	0.311
Creatine kinase	10.88 ± 6.64	12.71 ± 7.86	−0.742	0.463
NT-proBNP	9.67 ± 13.30	20.33 ± 23.29	−0.958	0.352
Glutamic pyruvic transaminase	34.18 ± 21.89	30.36 ± 23.85	0.493	0.625
Albumin	38.01 ± 3.97	37.12 ± 2.87	0.759	0.453
γ-glutamyl transpeptidase	65.01 ± 38.64	58.23 ± 51.38	0.421	0.677
Total bilirubin	12.63 ± 7.23	11.92 ± 4.71	0.34	0.736
Creatinine	73.86 ± 28.85	69.95 ± 15.50	0.504	0.618
Urea nitrogen	4.83 ± 2.41	4.75 ± 1.32	0.127	0.900
Glutamic oxaloacetic transaminase	24.04 ± 11.63	25.21 ± 13.46	−0.279	0.782
Procalcitonin	0.078 ± 0.081	0.047 ± 0.025	1.4	0.174

Data are mean ± SD. NT-proBNP: N-terminal-pro-brain natriuretic peptide.